Robert W. Baird Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA)

Robert W. Baird assumed coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report published on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $30.00 price objective on the stock.

IDYA has been the topic of several other research reports. Jefferies Financial Group initiated coverage on IDEAYA Biosciences in a report on Monday, June 17th. They set a buy rating and a $14.00 price objective on the stock. Citigroup initiated coverage on IDEAYA Biosciences in a report on Monday, June 17th. They set a buy rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase & Co. initiated coverage on IDEAYA Biosciences in a report on Monday, June 17th. They set a neutral rating and a $15.00 price objective on the stock.

NASDAQ:IDYA traded up $0.08 during trading hours on Monday, hitting $8.19. 300 shares of the stock were exchanged, compared to its average volume of 39,712. The company’s 50 day moving average is $6.78. IDEAYA Biosciences has a twelve month low of $5.42 and a twelve month high of $16.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.95 and a current ratio of 18.94.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.66). On average, equities analysts predict that IDEAYA Biosciences will post -3.02 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of IDYA. Cubist Systematic Strategies LLC acquired a new position in shares of IDEAYA Biosciences in the 2nd quarter valued at $49,000. BlackRock Inc. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at $82,000. Laurion Capital Management LP bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at $199,000. Vanguard Group Inc. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at $349,000. Finally, Monashee Investment Management LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at $354,000. 25.12% of the stock is currently owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Featured Article: Find a Trading Strategy That Works

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.